# Atlas Venture

> Atlas Venture is a VC fund backing Biotechnology and Health Care. See 438 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 438
- Last investment: Jun 2026
- Lead investor: 29%
- Last fund: Mar 2022
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/atlas-venture
- X (Twitter): http://twitter.com/atlasventure
- Website: http://atlasventure.com
- Facebook: http://www.facebook.com/pages/Atlas-Venture/179492238740381

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

## Contacts

5 contacts available for Atlas Venture. Shizune tracks 20 team members at Atlas Venture. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/atlas-venture?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $3.5M–$92M |
| Series B | $8M–$115M |
| Series C | $6M–$95M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 97 | 22% |
| Health Care | 59 | 13% |
| Therapeutics | 50 | 11% |
| Medical | 42 | 10% |
| Software | 38 | 9% |

194 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 126 | 29% |
| Series B | 94 | 21% |
| Series C | 48 | 11% |
| Seed | 44 | 10% |
| Funding Round | 36 | 8% |

13 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 182 | 42% |
| United Kingdom | 20 | 5% |
| Canada | 5 | 1% |
| France | 5 | 1% |
| Germany | 5 | 1% |

13 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chelsea Place Johnson | Principal | 2 | https://shizune.co/investors/profile/chelsea-place-johnson |
| Ed Holson | Entrepreneur-in-Residence | 0 | https://shizune.co/investors/profile/ed-holson |
| Jean-Francois Formela | Partner | 21 | https://shizune.co/investors/profile/jean-francois-formela |
| Kevin Bitterman | Partner | 28 | https://shizune.co/investors/profile/kevin-bitterman |
| Michael Gladstone | Principal | 16 | https://shizune.co/investors/profile/michael-gladstone |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Triveni Bio | Triveni Bio is at the forefront of human genetics, cutting-edge antibody design, and precision medicine, pioneering the identification of new disease targets. | $65M | Series C | Jun 17, 2026 |  |
| Q32 Bio | Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.Q32 Bio consists of ateam of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies. | $55M | Post-IPO Equity | May 26, 2026 |  |
| Vima Therapeutics | Vima Therapeutics operates as a biotechnology company.Vima Therapeutics creates a new era in treatments for dystonia and related movement disorders. | $40M | Series A | Mar 11, 2026 |  |
| Kinaset Therapeutics | Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M | Series B | Jan 10, 2026 |  |
| Diagonal Therapeutics | Diagonal Therapeutics is a biotechnology startup that is pioneering a novel technique to finding and producing agonist antibodies. Diagonal Therapeutics platform combines novel computational and experimental methodologies to solve the traditional obstacles associated with agonist antibody drug development. | $125M | Series B | Jan 08, 2026 |  |
| Triana Biomedicines | Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $120M | Series B | Dec 03, 2025 |  |
| Lifordi Immunotherapeutics | Lifordi Immunotherapeutics is a biotech company that provides antibody-drug conjugates for autoimmune and inflammatory disorders. | $42M | Venture - Series Unknown | Nov 19, 2025 |  |
| AAVantgarde Bio | AAVantgarde Bio is developing gene therapies for inherited retinal disorders. | $141M | Series B | Nov 03, 2025 |  |
| Affinia Therapeutics | Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle andcentral nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties. | $40M | Series C | Oct 07, 2025 |  |
| Renasant Bio | Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments. | $54.5M | Seed | Jul 10, 2025 |  |

10 of 438 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 30 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 24 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 23 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 18 deals together
- [Omega Funds](https://shizune.co/investors/profile/omega-funds) — VC Fund, 18 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 17 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Health Care Investors](https://shizune.co/investors/health-care-investors)
- [Health Care VC Funds](https://shizune.co/investors/health-care-vc-funds)
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)

## FAQ

### What does Atlas Venture invest in?

Atlas Venture invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 438 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Atlas Venture's check size?

Atlas Venture typically joins rounds of $3.5M–$92M at Series A, $8M–$115M at Series B and $6M–$95M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Atlas Venture participates in.

### How do I contact Atlas Venture?

Public channels for Atlas Venture include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Atlas Venture?

The team at Atlas Venture includes Chelsea Place Johnson (Principal), Ed Holson (Entrepreneur-in-Residence) and Jean-Francois Formela (Partner), among 20 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co